Salvo Health Secures $8.5M to Transform GI and Metabolic Care
January 27, 2026, 9:38 pm
Salvo Health, a New York digital health innovator, raised $8.5 million in Series A funding. The investment propels its virtual and hybrid care platform. Salvo specializes in chronic gastrointestinal and metabolic health. Funds will expand its AI engineering team and national network of dietitians, behavioral health professionals, and nurses. The company achieved 800% growth in patients and revenue in 2025. It now partners with 801 gastroenterologists across 10 states. Salvo's platform delivers continuous, specialized care. It addresses conditions like IBS, IBD, GERD, and obesity. This funding enhances access to expert care, improving outcomes for millions. Salvo solidifies its role in healthcare transformation.
New York City, NY – Salvo Health has closed a significant Series A funding round. The digital health company secured $8.5 million. This investment bolsters its mission. Salvo Health focuses on advanced gastrointestinal and metabolic health solutions. The funding round saw robust participation. It underscores confidence in Salvo’s innovative care model.
ManchesterStory co-led the financing. City Light Capital also took a lead position. Threshold Ventures joined as a co-leader. Several new investors participated. The Artemis Fund made a commitment. Contour Venture Partners invested. Owl Capital contributed. Impact X Capital Partners also joined the round. Existing investors reinforced their support. Human Ventures returned. Torch Capital continued its backing. Felicis Ventures participated again. Alumni Ventures reiterated its confidence. The round brings Salvo’s total equity raised to $21.6 million. This substantial capital injection empowers future growth.
Salvo Health is redefining chronic care. The company operates a unique virtual and hybrid care platform. It specifically targets gastrointestinal (GI) and metabolic conditions. Millions of Americans suffer from these ailments. Common issues include Irritable Bowel Syndrome (IBS). Inflammatory Bowel Disease (IBD) is another focus. Gastroesophageal Reflux Disease (GERD) is addressed. Celiac disease patients benefit. Gastroparesis management is offered. Metabolic conditions are also key. These include MASLD and general obesity. Salvo provides comprehensive solutions for complex health challenges.
The platform offers continuous care. This approach supports patients beyond clinic walls. It combines in-clinic services with AI-supported continuous monitoring. This hybrid model enhances traditional healthcare delivery. It allows direct access to a specialized gut-focused care team. This team includes crucial healthcare professionals. Registered dietitians provide nutritional guidance. Behavioral health professionals offer vital support. Nurses manage ongoing care needs. This multidisciplinary team ensures holistic patient treatment.
Funds from the Series A round have clear objectives. Salvo Health plans to expand its engineering team. This expansion is critical. It supports an AI-led roadmap. Artificial intelligence will further personalize patient care. It will also streamline operational efficiencies. The company will also accelerate national hiring. More registered dietitians are needed. Behavioral health professionals will join the team. Additional nurses are a priority. This strategic hiring surge meets increasing patient demand. It ensures high-quality care delivery at scale.
Salvo Health’s growth trajectory has been remarkable. The company posted exceptional results in 2025. Patient numbers surged. Revenue experienced explosive growth. Both metrics increased by 800% year-over-year. Enterprise agreements with GI practices also expanded dramatically. These partnerships grew by over 1,000%. Salvo has solidified its presence nationwide. It signed agreements with 801 gastroenterologists. This represents approximately 16% of independent GIs in the United States. Such penetration highlights its significant market impact.
The company collaborates with major healthcare providers. Its enterprise customers include three of the four largest GI practices. These partnerships are extensive. They span ten states. Collectively, these practices serve over 1.1 million patients annually. Salvo Health empowers these brick-and-mortar clinics. It provides them with a continuous care platform. This platform offers multiple benefits. Clinics can save time. They can increase their revenue streams. Most importantly, patient outcomes improve significantly.
Chronic GI conditions affect a vast population. Over 100 million Americans endure these issues. Access to specialized care remains a major obstacle. Many communities face shortages of GI providers. Salvo Health directly addresses this gap. It expands access to "whole person" care. Its platform allows community GI practices to build "Center of Excellence" care. This model offers world-class, multidisciplinary, team-based support. Patients receive the comprehensive care they desperately need.
The integration of AI technology is a cornerstone of Salvo’s strategy. AI development will refine predictive analytics. It will enhance personalized treatment plans. It allows for more efficient resource allocation. This technology supports both patients and providers. It helps identify patterns in patient data. It suggests optimal interventions. This leads to better, faster health improvements. AI also aids in scaling services. It maintains quality as the company grows.
Salvo Health was founded in 2021. Its rapid ascent demonstrates a clear market need. Jeffrey Glueck leads the company as CEO. Marin Rothenberg serves as COO. Dr. Erin Hendriks is CMO. This leadership team drives Salvo’s innovative vision. They are committed to transforming chronic care management. They aim to make expert care accessible to all. The company's platform has proven outcomes for complex conditions. It provides significant relief for sufferers of IBD, IBS, GERD, celiac, gastroparesis, MASLD, and obesity.
This latest funding round marks a pivotal moment. It accelerates Salvo Health’s expansion plans. It strengthens its technological capabilities. It deepens its clinical team. The company is poised for continued disruption in digital health. It will further its mission to deliver unparalleled gastrointestinal and metabolic health solutions. Salvo Health is setting a new standard. It offers hope and healing for millions living with chronic conditions. The future of integrated GI and metabolic care looks brighter.
New York City, NY – Salvo Health has closed a significant Series A funding round. The digital health company secured $8.5 million. This investment bolsters its mission. Salvo Health focuses on advanced gastrointestinal and metabolic health solutions. The funding round saw robust participation. It underscores confidence in Salvo’s innovative care model.
ManchesterStory co-led the financing. City Light Capital also took a lead position. Threshold Ventures joined as a co-leader. Several new investors participated. The Artemis Fund made a commitment. Contour Venture Partners invested. Owl Capital contributed. Impact X Capital Partners also joined the round. Existing investors reinforced their support. Human Ventures returned. Torch Capital continued its backing. Felicis Ventures participated again. Alumni Ventures reiterated its confidence. The round brings Salvo’s total equity raised to $21.6 million. This substantial capital injection empowers future growth.
Salvo Health is redefining chronic care. The company operates a unique virtual and hybrid care platform. It specifically targets gastrointestinal (GI) and metabolic conditions. Millions of Americans suffer from these ailments. Common issues include Irritable Bowel Syndrome (IBS). Inflammatory Bowel Disease (IBD) is another focus. Gastroesophageal Reflux Disease (GERD) is addressed. Celiac disease patients benefit. Gastroparesis management is offered. Metabolic conditions are also key. These include MASLD and general obesity. Salvo provides comprehensive solutions for complex health challenges.
The platform offers continuous care. This approach supports patients beyond clinic walls. It combines in-clinic services with AI-supported continuous monitoring. This hybrid model enhances traditional healthcare delivery. It allows direct access to a specialized gut-focused care team. This team includes crucial healthcare professionals. Registered dietitians provide nutritional guidance. Behavioral health professionals offer vital support. Nurses manage ongoing care needs. This multidisciplinary team ensures holistic patient treatment.
Funds from the Series A round have clear objectives. Salvo Health plans to expand its engineering team. This expansion is critical. It supports an AI-led roadmap. Artificial intelligence will further personalize patient care. It will also streamline operational efficiencies. The company will also accelerate national hiring. More registered dietitians are needed. Behavioral health professionals will join the team. Additional nurses are a priority. This strategic hiring surge meets increasing patient demand. It ensures high-quality care delivery at scale.
Salvo Health’s growth trajectory has been remarkable. The company posted exceptional results in 2025. Patient numbers surged. Revenue experienced explosive growth. Both metrics increased by 800% year-over-year. Enterprise agreements with GI practices also expanded dramatically. These partnerships grew by over 1,000%. Salvo has solidified its presence nationwide. It signed agreements with 801 gastroenterologists. This represents approximately 16% of independent GIs in the United States. Such penetration highlights its significant market impact.
The company collaborates with major healthcare providers. Its enterprise customers include three of the four largest GI practices. These partnerships are extensive. They span ten states. Collectively, these practices serve over 1.1 million patients annually. Salvo Health empowers these brick-and-mortar clinics. It provides them with a continuous care platform. This platform offers multiple benefits. Clinics can save time. They can increase their revenue streams. Most importantly, patient outcomes improve significantly.
Chronic GI conditions affect a vast population. Over 100 million Americans endure these issues. Access to specialized care remains a major obstacle. Many communities face shortages of GI providers. Salvo Health directly addresses this gap. It expands access to "whole person" care. Its platform allows community GI practices to build "Center of Excellence" care. This model offers world-class, multidisciplinary, team-based support. Patients receive the comprehensive care they desperately need.
The integration of AI technology is a cornerstone of Salvo’s strategy. AI development will refine predictive analytics. It will enhance personalized treatment plans. It allows for more efficient resource allocation. This technology supports both patients and providers. It helps identify patterns in patient data. It suggests optimal interventions. This leads to better, faster health improvements. AI also aids in scaling services. It maintains quality as the company grows.
Salvo Health was founded in 2021. Its rapid ascent demonstrates a clear market need. Jeffrey Glueck leads the company as CEO. Marin Rothenberg serves as COO. Dr. Erin Hendriks is CMO. This leadership team drives Salvo’s innovative vision. They are committed to transforming chronic care management. They aim to make expert care accessible to all. The company's platform has proven outcomes for complex conditions. It provides significant relief for sufferers of IBD, IBS, GERD, celiac, gastroparesis, MASLD, and obesity.
This latest funding round marks a pivotal moment. It accelerates Salvo Health’s expansion plans. It strengthens its technological capabilities. It deepens its clinical team. The company is poised for continued disruption in digital health. It will further its mission to deliver unparalleled gastrointestinal and metabolic health solutions. Salvo Health is setting a new standard. It offers hope and healing for millions living with chronic conditions. The future of integrated GI and metabolic care looks brighter.